Purpose: Reduced heart rate variability significantly increases cardiovascular mortality. Metabolic syndrome increases the cardiac autonomic dysfunction. Recently, increasing cardiovascular mortality has been reported in patients with schizophrenia. This study was done to compare heart rate variability between adults with and without schizophrenia and to compare the relationship of heart rate variability to metabolic syndrome in hospitalized patients with schizophrenia. Methods: This was a descriptive and correlational study in which 719 adults without schizophrenia and 308 adults with schizophrenia took part between May and June 2008. We measured the following: five-minute heart rate variability; high-frequency, low-frequency, the ratio of low-frequency to high-frequency, and the Standard Deviation of all the normal RR intervals. Data was also collected on metabolic syndrome, abdominal obesity, triglycerides, HDL cholesterol, blood pressure and fasting glucose. Results: The Standard Deviation of all the normal RR intervals values of heart rate variability indices were 1.53±0.18. The low-frequency and high-frequency values of heart rate variability indices were significantly higher in hospitalized patients with schizophrenia (3.89±1.36; 3.80±1.20) than those in the healthy participants (2.20±0.46; 2.10±0.46). There were no significant differences between the schizophrenic patients with and without metabolic syndrome. Conclusion: The results of this study indicate that schizophrenia patients have significantly lower cardiac autonomic control, but they have significantly higher low-frequency and high-frequency values than those of healthy adults. Use of antipsychotic drug may affect the autonomic nervous system in schizophrenic patients. Metabolic syndrome was not associated with cardiac autonomic control in schizophrenia patients.
INTRODUCTION
Heart rate variability (HRV) represents cardiac autonomic control and reduced HRV significantly increases cardiovascular mortality (La Rovere, Bigger, Marcus, Mortara, & Schwartz, 1998; La Rovere et al., 2001) . It is also generally known that time and frequency domain indices quantifying HRV are reduced in conditions such as diabetes (Kudat et al., 2006) and obesity (Karason, Molgaard, Wikstrand, & Sjostrom, 1999; Kim et al., 2005) . HRV provides quantitative information about the autonomic function and balance of the autonomic nervous system (ANS) through non-invasive indices of cardiac autonomic modulation (van Ravenswaaij-Arts, Kollee, Hopman, Stoelinga, & van Geijn, 1993) . A majority of studies have focused on patients with the diagnoses of coronary disease and neuropathies, but in recent years investigation of cardiac autonomic function has extended into other conditions including inpatients with schizophrenia in whom increased cardiovascular mortality was reported (Kelly et al., 2010) . The SDNN is a strong indicator of the cardiovascular stability and ability of the ANS to control the body system (Montano et al., 1994) .
The representation of LF and HF in normalized units emphasizes the controlled and balanced behavior of the two branches of the autonomic nervous system. The ratio of low to high frequency (LF/HF) is the ratio of sympathetic nervous system (SNS) to parasympathetic nervous system (PNS) (Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology, 1996) .
The relationship between HRV and metabolic syndrome in general population was elucidated by many researchers (Kuch et al., 2001; Lee et al., 2004; Oh, Hong, Sung, & Barrett-Connor, 2004 ).
HRVs in diabetes and obesity were found to be associated with metabolic syndrome and it was found to increase the cardiac autonomic dysfunction (Astrup et al., 2006) . The use of antipsychotics in schizophrenia apparently to improve psychotic symptoms, the metabolic effects of atypical antipsychotics have received particular attention in the literature as accrued experience demonstrates marked differences between various agents in their risk for weight gain and changes in serum triglycerides and glycemic control (Meyer, 2001) . A high prevalence of metabolic syndrome has been reported among schizophrenic patients Meyer et al., 2005; Sugawara et al., 2011) . In the study of Sugawara et al., they compared the metabolic syndrome prevalence between inpatients and outpatients among schizophrenic population in Japan. The result was reported that outpatients with schizophrenia or schizoaffective disorder in Japan had a high prevalence of metabolic syndrome compared to inpatients.
However, limited studies exist in the literature that examined the relationship between HRV and metabolic syndrome in schizophrenic patients. This study aimed to fill the gap in the literature.
Specific aims of the study were to compare heart rate variability between healthy adults and hospitalized patients with schizophrenia, and to examine the relationships of HRV to metabolic syndrome in hospitalized patients with schizophrenia.
METHODS

Study population
Data were collected from 719 healthy adults (H participants: 510 male patients and 209 female patients) who visited the outpatient clinic of a major university hospital for annual checkup and 308 patients (207 male patients and 100 female patients) who were hospitalized with the diagnosis of DSM-IV schizophrenia (S participants) at two hospitals and one sanatorium in two cities that were geographically closely. www.kan.or.kr (Colin). The fasting blood sugar was measured by Toshiba (Japan).
Sitting blood pressure was measured by the random zero sphygnomanometer after a 5-minute rest.
Permission for accessing and using the data was obtained from the directors of the hospitals and outpatient clinic (they didn't have formalized Institutional Review Board [IRB] procedure). All H and S participants who were asked to participate in the research agreed and signed the informed consent. Consents from S participants were obtained from family members over the telephone.
ANS dysfunction and reduced HRV have been reported in a wide variety of normal people, but have not been well characterized in schizophrenia. We recorded cardiac activity and assessed HRV in hospitalized schizophrenia (SCZ) patients compared to healthy comparison (HC) participants.
Non-spectral HRV analysis
In the time domain analysis of HRV, the standard deviation of all RR intervals (SDNN), the square root of the mean squared differences of successive normal sinus intervals (RMSSD) were computed. SDNN estimates global HRV, mediated by sympathetic and parasympathetic nervous systems.
Spectral HRV analysis
In the frequency domain, spectral analysis was performed using 
Statistical analysis
For statistical analyses, SPSS for Windows Program (version 15.0) and Stata ® 11.1 were used. All data were tested for normality using the Kolmogorov-Smimov test. To normalize skewed HRV variables, a logarithmic transform was applied. Group differences of general characteristics between H and S participants were analyzed by Chisquare test.
Logistic regression analyses were used for the values of adjusted odds ratio (AOR) and 95% confidence interval (CI) by using median of HRV variables between H and S participants.
Kernel Density Estimation was used for comparisons of the distributions of LF and HF between the two groups (H and S participants group). Statistical significance was determined as p< .05.
RESULTS
Sample Characteristics
The determinants of short-period HRV in 719 H participants and 307 S participants are shown in Table 1. The mean age of H participants was 49.5± 8.7 years, and S participants was 51.1± 9.8 years, and the age difference was significant between the two groups (p < .001) (Table 1) .
Linear HRV indices between H participants and S participants
When age was used as covariate, H participants showed significantly higher SDNN and RMSSD values than those of S participants (p < .001), while S participants showed significantly higher LF and HF values (p < .001) than those of H participants. SDs were similar for SDNN and RMSSD in both groups, but mean SD values of both LF and HF of S participants were nearly 3 times larger than those of 
DISCUSSION
The objective of the current study used HRV to test autonomic function of the heart, and compared HRV between healthy adults and hospitalized patients with schizophrenia in Korea.
Hospitalized patients with schizophrenia exhibited a decrease of SDNN and RMSSD in HRV compared to healthy participants group.
As expected, SDNN and RMSSD of healthy participants group showed significantly higher values than those of inpatients with Logistic regression analyses adjusted with all above variables. AOR=Adjusted odds ratio; 95% CI=95% confidence interval; SDNN = Standard deviation of all normal RR intervals; RMSSD= Root mean square of successive differences; LF=Low-frequency; HF=High-frequency; LF/HF: The ratio of low to high frequency. (Bar et al., 2005; Birkhofer, Alger, Schmid, & Forstl, 2007; Boettger et al., 2006) . In schizophrenia, autonomic dysregulation is associated with more severe psychiatric symptoms, suggesting HRV dysfunction in this disorder may be dependent on the phase of the illness Boettger et al.; Henry, Minassian, Paulus, Geyer, & Perry, 2010) .
Decreased HRV was found to be associated with a pathological conditions like metabolic syndrome (Liao, Carnethon, Evans, Cascio, & Heiss, 2002) and low SDNN was reported as having an independent prognostic value for cardiac mortality (La Rovere et al., 2001 ).
In logistic regression analyses, total participants without metabolic syndrome were significantly associated with SDNN (AOR, 1.70; 95%
CI, 1.09-2.64). Taken as a whole, these data indicate that SDNN of total participants group without metabolic syndrome demonstrated significantly higher values than those of total participants group with metabolic syndrome. This suggests that total participants group without metabolic syndrome showed more cardiovascular stability and ability of the ANS to control the body system than total participants group with metabolic syndrome. As expected, H participants group were significantly associated with SDNN (AOR, 2.13; 95% CI, Program (Grundy et al., 2004) , the prevalence rate of metabolic syndrome in hospitalized patients with schizophrenia was 19.9%, in same inpatient population were 36-37%, which was higher than that of general populations (Lee et al., 2004; Suvisaari et al., 2007) . In Korea, the prevalence of metabolic syndrome was 16.0% in men and 10.7% in women aged 30-80 years (Oh, Hong, Sung, & Barrett-Con- These finding has implications with the fact that significantly higher LF and HF indices shown in S participants than that of healthy participants in this study may be explained in part by the use of antipsychotic drugs that all S participants were taking. These medicines may have affected autonomic nervous system as a mediating factor between metabolic syndrome and HRV in these patients. Agelink et al. (2001) suggested neurocardiac effects of atypical neuroleptics (amisulpride, olanzapine, clozapine and sertindole) on ANF should exert distinct effects on ANF depending on the extent to which anticholinergic and/or antiadrenergic effects. In this study, S participants were on various antipsychotic drugs. Heart rate deceleration capacity is significantly reduced in schizophrenic patients treated with antipsychotics and may serve as an indicator of increased cardiovascular mortality risk (Birkhofer, Alger, Schmid, & Forstl, 2007) .
Patients treated with neuroleptic medications, especially clozapine, showed autonomic dysregulation and cardiac repolarization changes.
Physicians should be aware of this adverse reaction (Cohen, Loewenthal, Matar, & Kotler, 2001 ).
Other result showed significant increases in the mean, variance and HF of RR intervals in the amisulpride group, but not in the olanzapine group (Wang, Yang, Bai, & Kuo, 2008) . These results indicate that amisulpride has a more vagotonic effect, suggesting greater cardiovascular safety as compared with olanzapine when participants are switched from typical antipsychotic agents. In the present study, HRV was investigated during treatment with olanzapine. After 4 weeks of olanzapine medication, HRV was assessed during different sleep stages both in the time and frequency domains. Only slight changes in HRV were shown during treatment, and appeared to be independent of sleep stages. Spectral analysis indicated a slight shift of the sympathovagal balance in favour of the sympathetic tone, which was consistent with an elevation of heart rate in the time domain; total HRV was not altered. These changes are in accordance with olanzapine's receptor profile exerting anticholinergic and anti-adrenergic properties (Mann et al., 2004) .
These findings suggest that the effects of combination psychotropic drug treatment on HRV are mainly due to their anticholinergic properties (Ikawa et al., 2001) . We cannot rule out potential effects of antipsychotic drugs or schizophrenic symptoms because the metabolic syndrome may be associated with HRV differently in inpatients with schizophrenia due to antipsychotic polypharmacy (Agelink et al., 2001) .
Major limitations of this study include: lack of information on medication profile of hospitalized patients with schizophrenia; the use of medical records that might have included incomplete information; and the use of convenience samples in three hospital settings in two different cities although they were nearby to each other with similar sociodemographic profiles.
CONCLUSIONS
Hospitalized patients with schizophrenia showed significantly lower cardiac autonomic control, but they had significantly higher LF and HF values than those of healthy participants. A reduced cardiac autonomic control was not associated with metabolic syndrome in hospitalized patients with schizophrenia. Antipsychotic polypharmacy may have affected autonomic nervous system function as a mediating factor between metabolic syndrome and HRV in these patients.
